fda glp-1 warning letters september 2025 news 8, 2025: launches an import alert listing safe manufacturers – Partnership for Safe Medicines FDA Drug Recalls and Warnings:

Kuo CC, Chuang MH, Li CH, et al

10 Liraglutide was generally well tolerated

Adherence is significantly lower among those using GLP-1s for weight loss versus those using them to manage type 2 diabetes one study found that about 65% of patients without type 2 diabetes discontinued GLP-1 therapy within one year, compared to 47% of patients with type 2 diabetes

Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics

Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial